Background To explore the utility of the International Working Group (IWG)-1 criteria in
recruitment for Alzheimer's disease (AD) clinical trials, we applied the more recently …

As research evolves in prodromal AD, the need to validate sufficiently sensitive outcome
measures, eg the Alzheimer's Disease Composite Score (ADCOMS) is clear. In the …

Abstract Background The National Institute on Aging and Alzheimer's Association (NIA-AA)
have proposed a new Research Framework: Towards a biological definition of Alzheimer's …

Amyloid and tau pathological accumulation should be considered for Alzheimer's disease
(AD) definition and before subjects' enrollment in disease-modifying trials. Although age …

amyloid PET positivity, would the treated patients be considered AD-free? We believe that
these individuals clearly still have a neurodegenerative disease, and that this disease is AD …

Abstract The Wisconsin Registry for Alzheimer's Prevention is a longitudinal observational
cohort study enriched with persons with a parental history (PH) of probable Alzheimer's …

Introduction Returning research results that indicate risk of Alzheimer disease (AD)-a
disease for which no meaningful treatments or cure exist-to cognitively normal participants is …

Background Criteria for the clinical diagnosis of Alzheimer's disease (AD) were established
in 1984, and they needed to be updated and revised, in vue of the scientific knowledge …

Background: Age may affect treatment outcome in trials of mild probable Alzheimer's
disease (AD). Objective: We examined age as a moderator of outcome in an exploratory …

Alzheimer's disease (AD) progresses through a lengthy asymptomatic period during which
pathological changes accumulate prior to development of clinical symptoms. As disease …